Condensed Consolidated Statements of Cash Flows $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)
Cash flows from operating activities:
Net loss	$ (212,714)	$ (14,172)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization	1,117	306
Amortization of right-of-use asset	390	165
Accretion of discounts on marketable securities	(2,363)	332
Share-based compensation expense	10,278	3,340
Charge for purchase of in-process research and development assets	124,972
Changes in operating assets and liabilities:
Prepaid expenses and other assets	2,269	1,553
Accounts payable	256	71
Accrued expenses and other current liabilities	13,507	(1,452)
Deferred revenue	(6,303)	19,808
Operating lease liabilities	(143)	(60)
Net cash (used in) provided by operating activities	(68,734)	9,891
Cash flows from investing activities:
Purchases of in-process research and development assets	(46,086)
Purchases of marketable securities	(112,688)
Maturities of marketable securities	70,000
Purchases of property and equipment	(6,047)	(482)
Net cash used in investing activities	(94,821)	(482)
Cash flows from financing activities:
Proceeds from public offering	230,002
Payment of offering costs	(14,828)	(125)
Prepayments from PIPE transaction recorded as deposit liability		61,000
Proceeds from exercise of stock options	1,539
Proceeds from exercise of common stock warrants	3,731
Proceeds from issuance of common stock under prior ATM, net		34
Net cash provided by financing activities	220,444	60,909
Net increase in cash and cash equivalents and restricted cash	56,889	70,318
Cash and cash equivalents and restricted cash at beginning of period	98,779	20,423
Cash and cash equivalents and restricted cash at end of period	155,668	90,741
Reconciliation of cash and cash equivalents and restricted cash:
Cash and cash equivalents	155,568	90,641
Restricted cash	100	100
Total cash, cash equivalents, and restricted cash	155,668	90,741
Supplemental disclosures of non-cash investing and financing activities:
Issuance of common stock in exchange for in-process research and development assets	76,732
Net liabilities assumed from purchases of in-process research and development assets	2,041
Purchase of in-process research and development assets in accounts payable	113
Right-of-use assets obtained in exchange for operating lease liabilities	1,189
Remeasurement of operating right-of-use asset and lease liability due to lease extension		226
Issuance of common stock to certain board of directors in lieu of accrued compensation		221
Offering costs in accounts payable and accrued expenses and other current liabilities		5
Purchases of property and equipment in accounts payable and accrued expenses and other current liabilities	$ 541	$ 315